Russian vaccine to prevent B-type hepatitis to hit global market

Print 16 May 2016
Marchmont Innovation News

A new Russian vaccine to prevent B-type hepatitis is entering the global market. According to experts, taking an injection with the new vaccine will give a person long-term confidence as it is said to stay active for many years. 

“This is a unique vaccine from the standpoint of the ideology of its development. It contains no biocomponents or biological tissues of a sick person, which has been widespread in developing the prior generations of vaccines. This new vaccine is absolutely genetically engineered and based on a high-specificity virus active in the Russian Federation,” explained Igor Nikitin who heads the hospital therapy chair at the Moscow-based Pirogov Russian National Research Medical University.

The vaccine is said to have emerged a few years ago already in the labs of Kombiotech, a Moscow-based biotech company. The developer has reportedly been manufacturing an estimated five million ampoules of the vaccine a year for domestic consumption.

Source

Return